Clinical trial

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

NCT02951637

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Pemetrexed plus carboplatin combined with gefitinib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gefitinib Normalized identity: gefitinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-12-01

PhasePHASE2

Conditions

Lung Adenocarcinomaverified · MONDO: lung adenocarcinoma

Interventions

Pemetrexed plus carboplatin combined with gefitinibDRUG

GefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

Shanghai Chest Hospitallead sponsor

Ruijin Hospitalcollaborator

Changhai Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02951637 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.